PROQUIL™

NATURAL PROSTATE SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

Supplementary management of Benign Prostatic Hypertrophy with PROSTAQUIL™ (*PROQUIL™) : A 8-week registry.

Belcaro G, Dugall M, Luzzi R, Ledda A, Pellegrini L, Hosoi M, Errichi BM, Francis S, Cornelli U. Irvine3 Labs, Dept or Med Biomed Sciences, CH-PE University, Italy

Internationally published clinical study on BPH patients with ProstaQuil™ (*PROQUIL™) shows:

61% Reduction in nocturia

58% Reduction in residual vesical volume

64% Improvement in quality of life

Significantly improves BPH symptoms



Minerva Gastroenterol Dietol. 2015 Oct 22.

ABSTRACT

The aim of this registry was to evaluate the management of initial symptoms of benign prostatic hyperthrophy (BPH) in otherwise healthy subjects, using ProstaQuil™ (Alchem) in a 8-week registry. ProstaQuil™ was used at the dosage of 200 mg/day. The product includes Pygeum extract (100 mg) & Saw palmetto oil (35 mg). The two resulting groups standard management & supplement were comparable.

RESULTS

No side effects or comparability problems were observed and compliance was optimal with more than 95% of the capsules correctly used. Empting, frequency, intermittency, urgency, weak flow, straining, nocturia were all significantly improved with ProstaQuil™ ($p<0.05$) and the improvement - globally and evaluating any single item - was significantly superior to the one observed in controls ($p<0.05$). Quality of life with the supplement was also significantly better in comparison with controls ($p<0.05$). The residual vesical volume was 94.7;5.8 ml in the supplement group at inclusion and decreased to 39.3;5 ml ($p<0.05$) at 8 weeks. This decrease was equivalent to a reduction of 58.5% (vs a decrease of 27.9% in controls) ($p<0.05$; ANOVA).

CONCLUSION

In conclusion – ProstaQuil™, a new generation of pharma-standard supplement – including Pygeum – is an important option for self-management in most uncomplicated patients with Benign Prostatic Hyperplasia (BPH)

*PROQUIL™ contains ProstaQuil™ formula.

ALEUI19040016

PROQUIL™

NATURAL PROSTATE SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

BPH: Variation in Prostate Volume and Vesical Volume; Effects of ProstaQuil™ (*PROQUIL™)

Ledda A., Belcaro G., Dugall M., Irvine3 Labs, Dept or Med Biomed Sciences, CH-PE University, Italy

Internationally published clinical study on effect of prostrate health and function with ProstaQuil™ (*PROQUIL™) shows:

- 60% Improvement in urinary frequency
- 59% Improvement in nocturia
- 55% Decrease in residual urinary volume

Significant improvement of prostate health & functions

International Journal of Pharma Standard (PS) Supplements, May 2016

ABSTRACT

This registry evaluated the management of initial symptoms of BPH in otherwise healthy subjects, using ProstaQuil™ (Alchem, India) in a supplement registry (150 days). The target of the registry was the supplementary management of initial, mild symptoms in subjects not using other drugs, who did not have previous surgical procedures or urinary retention and no significant infections in the 3 years before the registry.

RESULTS

The two resulting groups were comparable for age, symptoms distribution and ultrasound findings (both considering prostate volume and residual urinary volume). The days of follow up were comparable. No side effects or tolerability problems were observed and compliance was optimal with more than 97% of the capsules correctly used. Emptying, frequency, intermittency, urgency, weak flow, straining, nocturia were all significantly improved with ProstaQuil™ ($p<0.05$); the improvement – evaluating any single item was significantly superior to the improvement observed in controls ($p<0.05$). The most important target measurement (the residual vesical volume) decreased for 54.5 ml with the supplement group (vs 29 ml in controls). In the supplement group 4 out of 19 subjects had to use other drug (not more than 3 days) to control symptoms; in the control group 12 out of 29 patients used some other drug including anti-inflammatory agents or antibiotics ($p<0.05$). Urinary bacterial contamination was absent at inclusion and at the end of the study.

CONCLUSION

In conclusion – ProstaQuil™, a new generation of pharma-standard supplement – including Pygeum – is an important option for self-management in most uncomplicated patients with Benign Prostatic Hyperplasia (BPH).

*PROQUIL™ contains ProstaQuil™ formula.

PROQUIL™

NATURAL PROSTATE SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

BPH: Variations in Sexual Interactions & Activity with ProstaQuil™ (*PROQUIL™)

Ledda A., Belcaro G., Dugall M., Irvine3 Labs, Dept or Med Biomed Sciences, CH-PE University, Italy

Internationally published clinical study on effect of prostaQuil™ (*PROQUIL™) on sexual interactions in BPH patients shows:

- **59%** Overall improvement in sexual interaction
- **41%** Improvement in spontaneous urine flow volume
- **15%** Decrease in residual vesical volume

Significantly improves prostate health & functions and sexual interaction



International Journal of Pharma Standard (PS) Supplements, June 2016

ABSTRACT

This registry evaluated the management of initial symptoms of BPH in subjects using ProstaQuil™ (Alchem, India) in a supplement registry (150 days). The focus of this part of the registry was on sexual interactions. The target of the registry was the supplementary management of initial, mild symptoms in subjects not using other drugs, who did not have previous surgical procedures or urinary retention and no significant infections in the 3 years before the registry.

RESULTS

The two resulting groups were comparable for age, symptoms distribution and ultrasound findings (prostate volume and residual urinary volume). The days of follow up were comparable. No side effects or tolerability problems were observed and compliance was optimal. Spontaneous emptying was significantly increased with ProstaQuil™ and produced an almost 15% decrease in residual volume ($p<0.5$). The total volumes, as expected, were not changed. ProstaQuil™ appears to be more effective considering completed interactions and global satisfaction for sexual interactions. No urinary bacterial contamination was observed.

CONCLUSION

In conclusion – ProstaQuil™, a new generation of pharma-standard supplement – including Pygeum – is an important option for self-management in most uncomplicated patients with Benign Prostatic Hyperplasia (BPH) improving voiding and sexual functions.

*PROQUIL™ contains ProstaQuil™ formula.

PROQUIL™

NATURAL PROSTATE SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

ProstaQuil™ (*PROQUIL™) Safety Study: Non-Interference with Anti-Coagulants & Anti-Platelet Agents

Ledda A., Belcaro G., Dugall M., Irvine3 Labs, Dept or Med Biomed Sciences, CH-PE University, Italy

Internationally Published Clinical Safety Study of ProstaQuil™ (*PROQUIL™) shows:

No reduction in bleeding time with ProstaQuil™ (*PROQUIL™)

No interaction of ProstaQuil™ (*PROQUIL™) with anti-coagulating drugs

ProstaQuil™ (*PROQUIL™) does not change the action of anti-platelet and anti-coagulating agents.



International Journal of Pharma Standard (PS) Supplements, June 2016

ABSTRACT

This pilot study evaluates the effect of a new anti-inflammatory agent (based on Pygeum) on the antiplatelet action and anticoagulant activity in subjects using ProstaQuil™ for benign prostatic hypertrophy (BPH) for at least two weeks.

RESULTS

The bleeding time (BT) is the time taken for bleeding to stop after an incision is made into the skin, usually into the anterior surface of forearm. In this registry, BT in 10 subjects (age 63.2;3.3 males; no other treatments or clinical conditions) before ProstaQuil™ supplementation at the standard dosage was on average 4.25;1 (range 3-6.5) min. After 2 weeks of before ProstaQuil ™ supplementation the value was 4.22;1.2 (range 3.1-6) min. Anticoagulation was evaluated in 10 patients using Coumadin. Before the two weeks with the supplement their international normalized ratio (INR) was on average 2.94;0.2; after 2 weeks with the supplement the INR was basically unchanged (2.95;0.13).

CONCLUSION

In conclusion, ProstaQuil™ – in this pilot evaluation – does not change the antiplatelet action of the most common antiplatelet agents and does not seem to alter, in stable anti-coagulated patients, the needed dosage of anticoagulant treatment after two weeks of supplementation.

*PROQUIL™ contains ProstaQuil™ formula.

ALEUI19040016

PROQUIL™

NATURAL PROSTATE SUPPORT

– No Added Gluten –
– No Added Wheat –
– No Sugar –



DEVELOPED WITH PhytoAdvance® TECHNOLOGY

OVER 85 YEARS OF R&D CLINICALLY TESTED IN EUROPE

TRUSTED BY CUSTOMERS GLOBALLY

Proven Efficacy

ProstaQuil™ (*PROQUIL™) in BPH (Benign Prostatic Hypertrophy): A 6 months registry

Belcaro G., Dugall M., Ledda A., Hosoi M., Cornelli U. Irvine3 Labs, Dept or Med Biomed Sciences, CH-PE University, Italy.

Internationally published clinical study on treatment of patients suffering from BPH with ProstaQuil™ (*PROQUIL™) shows:

- Significant improvement in urinary emptying & frequency
- Significant improvement in nocturia
- Significant improvement in health related quality of life

ProstaQuil™ (*PROQUIL™) is safe, tolerable and improves prostate health & functions significantly

Preliminary Observation

International Journal of Pharma Standard (PS) Supplements, June 2016

ABSTRACT

This study evaluates the long-term (6-month) supplementary management with ProstaQuil™ in patients with benign prostatic hypertrophy (BPH). This study extends to 6 months the observations of our previously published study (an 8-week registry). The aim of this more extended 'SAFETY' registry was the evaluation of the symptomatic relief produced by ProstaQuil™ in the management of the most common initial symptoms of benign prostatic hyperthrophy (BPH) in otherwise healthy subjects. ProstaQuil™ (Alchem) was used at the dosage of 200 mg/day.

RESULTS

After almost 6 months no side effects or tolerability problems were observed and the compliance was considered optimal with more than 96% of the capsules correctly used. At 8 weeks, 3 and 5 months (while waiting for the final 6-month results), urinary emptying, frequency, intermittency, urgency, weak flow, straining, nocturia were all significantly improved with ProstaQuil ™ ($p<0.05$). The improvement - globally and evaluating any single item was significantly superior to the improvement observed in controls ($p<0.05$) using only standard management. The quality of life in the supplement group at 5 months was also significantly better in comparison with controls ($p<0.05$). The prostatic volume and the urinary residual vesical volume was significantly improved in the supplement group.

CONCLUSION

In conclusion, the most common symptoms of BPH are controlled by ProstaQuil™ a new standardized supplement including Pygeum and Saw palmetto oil with a very important safety and

*PROQUIL™ contains ProstaQuil™ formula.